清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Low- versus Standard-Dose Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke: An Updated Meta-Analysis

医学 改良兰金量表 置信区间 荟萃分析 优势比 内科学 脑出血 随机对照试验 子群分析 纤溶剂 临床终点 入射(几何) 组织纤溶酶原激活剂 外科 缺血性中风 缺血 蛛网膜下腔出血 物理 光学
作者
Huihui Liu,Huaguang Zheng,Yongjun Cao,Yuesong Pan,David Wang,Runhua Zhang,Shoujiang You,Xinmiao Zhang,Shuya Li,Xu Tong,Chun‐Feng Liu,Yilong Wang
出处
期刊:Journal of stroke and cerebrovascular diseases [Elsevier BV]
卷期号:27 (4): 988-997 被引量:12
标识
DOI:10.1016/j.jstrokecerebrovasdis.2017.11.005
摘要

Background We performed a meta-analysis to compare the efficacy and safety between low- and standard-dose intravenous (IV) tissue-type plasminogen activator (tPA) for acute ischemic stroke (AIS) patients within 4.5 hours of symptom onset. Methods We searched PubMed and EMBASE for relevant studies from inception to June1, 2017. Cohort or randomized controlled studies for AIS within 4.5 hours of symptom onset with comparison between low-dose and standard-dose tPA were included. The primary efficacy end point was favorable functional outcome (modified Rankin scale scores [mRS] of 0-1) at 90 days. The primary safety end point was the incidence rate of symptomatic intracerebral hemorrhage (sICH). The secondary end points were independent functional outcome (mRS scores of 0-2) and mortality. Results A total of 11 studies were pooled in this meta-analysis. The low-dose strategy appeared to be as effective as standard-dose tPA (43.4% versus 45.4%; odds ratio [OR] = 0.93, 95% confidence interval [CI]: 0.78-1.10; P = .38) in primary efficacy outcome. The secondary efficacy outcome produced similar results (57.3% versus 57.0%; OR = 0.95, 95% CI: 0.86-1.05; P = .33). There was no evidence of statistical difference for sICH (4.2% versus 4.9%; OR = 1.02 [0.66-1.55]; P = .94) and mortality (9.0% versus 10.6%; OR = 0.99 [0.74-1.31]; P = .92) at 90 days between low- and standard-dose therapy. In a subgroup analysis by ethnicity, there was no significant difference between patients of Asian and non-Asian descent for any of the end points. Conclusions This study showed that AIS patients receiving low-dose IV-tPA had comparably efficacy and safety to those receiving standard-dose IV-tPA. However, the effect is especially pronounced within the Asian population, which limits the generalizability of these results. We performed a meta-analysis to compare the efficacy and safety between low- and standard-dose intravenous (IV) tissue-type plasminogen activator (tPA) for acute ischemic stroke (AIS) patients within 4.5 hours of symptom onset. We searched PubMed and EMBASE for relevant studies from inception to June1, 2017. Cohort or randomized controlled studies for AIS within 4.5 hours of symptom onset with comparison between low-dose and standard-dose tPA were included. The primary efficacy end point was favorable functional outcome (modified Rankin scale scores [mRS] of 0-1) at 90 days. The primary safety end point was the incidence rate of symptomatic intracerebral hemorrhage (sICH). The secondary end points were independent functional outcome (mRS scores of 0-2) and mortality. A total of 11 studies were pooled in this meta-analysis. The low-dose strategy appeared to be as effective as standard-dose tPA (43.4% versus 45.4%; odds ratio [OR] = 0.93, 95% confidence interval [CI]: 0.78-1.10; P = .38) in primary efficacy outcome. The secondary efficacy outcome produced similar results (57.3% versus 57.0%; OR = 0.95, 95% CI: 0.86-1.05; P = .33). There was no evidence of statistical difference for sICH (4.2% versus 4.9%; OR = 1.02 [0.66-1.55]; P = .94) and mortality (9.0% versus 10.6%; OR = 0.99 [0.74-1.31]; P = .92) at 90 days between low- and standard-dose therapy. In a subgroup analysis by ethnicity, there was no significant difference between patients of Asian and non-Asian descent for any of the end points. This study showed that AIS patients receiving low-dose IV-tPA had comparably efficacy and safety to those receiving standard-dose IV-tPA. However, the effect is especially pronounced within the Asian population, which limits the generalizability of these results.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
美含完成签到 ,获得积分10
5秒前
西瓜完成签到 ,获得积分10
11秒前
13秒前
路过完成签到 ,获得积分10
18秒前
喜悦的香之完成签到 ,获得积分10
20秒前
文静元霜完成签到 ,获得积分10
21秒前
甜乎贝贝完成签到 ,获得积分10
25秒前
26秒前
科研通AI5应助威武鸵鸟采纳,获得30
27秒前
酷酷阑香发布了新的文献求助10
32秒前
John完成签到 ,获得积分10
33秒前
心想事成完成签到 ,获得积分10
36秒前
机灵的幻灵完成签到 ,获得积分10
40秒前
嘟嘟52edm完成签到 ,获得积分10
40秒前
看不见的美完成签到 ,获得积分10
49秒前
byron完成签到 ,获得积分10
51秒前
ww完成签到,获得积分10
52秒前
SC完成签到 ,获得积分10
53秒前
SCI完成签到 ,获得积分10
1分钟前
1分钟前
rora完成签到 ,获得积分10
1分钟前
颜色渐变完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
stiger完成签到,获得积分10
1分钟前
现代大神完成签到,获得积分10
1分钟前
正直的松鼠完成签到 ,获得积分10
1分钟前
勤劳的颤完成签到 ,获得积分10
2分钟前
2分钟前
儒雅的夏翠完成签到,获得积分10
2分钟前
2分钟前
zhang完成签到,获得积分10
2分钟前
PACEPANG完成签到 ,获得积分10
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
詹姆斯哈登完成签到,获得积分10
2分钟前
xz完成签到 ,获得积分10
2分钟前
小万完成签到 ,获得积分10
2分钟前
ssassassassa完成签到 ,获得积分10
2分钟前
ailemonmint完成签到 ,获得积分10
2分钟前
细心妙菡完成签到 ,获得积分10
2分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968559
求助须知:如何正确求助?哪些是违规求助? 3513358
关于积分的说明 11167340
捐赠科研通 3248714
什么是DOI,文献DOI怎么找? 1794453
邀请新用户注册赠送积分活动 875030
科研通“疑难数据库(出版商)”最低求助积分说明 804664